Annals of Surgical Oncology

, Volume 2, Issue 6, pp 542–549

Recombinant BCG therapy suppresses melanoma tumor growth

  • Rosemary B. Duda
  • Hua Yang
  • Danielle D. Dooley
  • Graziella Abu-Jawdeh
Original Articles

Abstract

Background: Melanoma is the fastest rising cancer in the United States. Bacillus Calmette-Guerin (BCG) has been genetically engineered to actively express and secrete the cytokine interleukin-2 (IL-2). Both BCG and IL-2 have known potent antitumor and immunomodulatory properties.

Methods: This recombinant BCG (rBCG 3A) has been tested as an intratumoral injection and a vaccine therapy in conjunction with irradiated tumor cells against melanoma in the murine B16 melanoma model.

Results: The transfection process did not adversely after the function of the wild-type (WT) BCG. rBCG 3A and WT BCG are equally effective intratumoral and vaccine therapies against melanoma when compared with normal saline control groups. Tumor burdens were significantly smaller (p</0.01 and 0.05) for the treatment groups for both intratumoral and vaccine administration of therapy. Immunization with rBCG 3A and WT BCG 14 days before a B16 challenge resulted in an ∼45% smaller tumor burden when compared with controls.

Conclusions: Novel therapies based on the immunogenic properties of melanoma combined with molecular technologies may offer promise for an effective and safe treatment of melanoma.

Key Words

Melanoma Vaccine BCG Immunotherapy Gene transfer Cytokines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© The Society of Surgical Oncology, Inc 1995

Authors and Affiliations

  • Rosemary B. Duda
    • 2
  • Hua Yang
    • 2
  • Danielle D. Dooley
  • Graziella Abu-Jawdeh
    • 1
  1. 1.Department of PathologyBeth Israel Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Division of Surgical OncologyBeth Israel HospitalBostonUSA

Personalised recommendations